A Prospective, Multi-Centric, Randomized, Double-Blind, Parallel, Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Shock Treatment
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Centhaquin (Primary)
- Indications Hypovolaemic shock
- Focus Registrational; Therapeutic Use
- Sponsors Pharmazz
- 03 Oct 2019 Status changed from recruiting to completed.
- 02 Aug 2019 Status changed from planning to recruiting.
- 28 Nov 2018 New trial record